Our top pick for
Beginners

Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ci&T Inc is a software-infrastructure business based in the US. CI&T shares (CINT) are listed on the NYSE and all prices are listed in US Dollars. CI&T employs 6,400 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
Latest market close | $9.70 |
---|---|
52-week range | $9.52 - $22.50 |
50-day moving average | $13.25 |
200-day moving average | $14.14 |
Wall St. target price | $19.44 |
PE ratio | 61.6875 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.16 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.7 from 2022-07-05
1 week (2022-06-29) | -7.62% |
---|---|
1 month (2022-06-07) | -29.91% |
3 months (2022-04-07) | -38.88% |
6 months (2022-01-07) | -12.93% |
1 year (2021-07-03) | N/A |
---|---|
2 years (2020-07-03) | N/A |
3 years (2019-07-03) | N/A |
5 years (2017-07-03) | N/A |
Valuing CI&T stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CI&T's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CI&T's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, CI&T shares trade at around 62x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, CI&T's P/E ratio is best considered in relation to those of others within the software-infrastructure industry or those of similar companies.
CI&T's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $305.2 million.
The EBITDA is a measure of a CI&T's overall financial performance and is widely used to measure a its profitability.
To put CI&T's EBITDA into context you can compare it against that of similar companies.
Revenue TTM | $1.6 billion |
---|---|
Operating margin TTM | 16.39% |
Gross profit TTM | $508.6 million |
Return on assets TTM | 11.3% |
Return on equity TTM | 19.15% |
Profit margin | 7.05% |
Book value | $7.61 |
Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting CI&T to pay a dividend over the next 12 months.
You may also wish to consider:
CI&T Inc. , together with its subsidiaries, provides strategy, design, and software engineering services to enable digital transformation for enterprises worldwide. It develops customizable software through the implementation of software solutions, including machine learning, artificial intelligence, analytics, and cloud and mobility technologies. The company was founded in 1995 and is headquartered in Campinas, Brazil. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.